Fermenta Biotech Ltd
Fermenta Biotech Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - No explicit future quantitative outlook for revenue or volumes is stated in the presentation. EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6 - The presentation does not explicitly state any margin outlook or guidance for future quarters in terms of EBITDA or operating margin.
From Fermenta Biotech Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8)
- Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8)
- Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7)
- Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5)
- Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5)
- German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5)
- EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Fermenta Biotech Ltd Q1 FY26 results?
Q1FY26 Revenue from operations: INR 136 crore, up 79% YoY (Page 8) - Total Income Q1FY26: INR 145 crore, up 79% YoY (Page 8) - Nutrition business revenue Q1FY26: INR 114.6 crore, up 85% YoY (Page 7) - Human Nutrition volume growth: 83% YoY, 8% QoQ (Page 5) - Animal Nutrition volume growth: 45% YoY, down 17% QoQ (Page 5) - German subsidiary Q1FY26 revenue: INR 15.7 crore, up 588% YoY (Page 5) - EBITDA Q1FY26 INR 37 crore, up 922% YoY (Page 6) - Profit after tax Q1FY26 INR 21.6 crore vs loss last year (Page 6) - No explicit future quantitative outlook for revenue or volumes is stated in the presentation. EBITDA for Q1FY26: INR 37 crore (up 922% YoY, down 9% QoQ) — Slide 6 - Operating EBITDA (without Real Estate): INR 35.3 crore (up 625% YoY, up 9% QoQ) — Slide 5 - Profit After Tax (PAT) for Q1FY26: INR 21.6 crore (vs INR 5.9 crore loss YoY, down 35% QoQ) — Slide 6 - The presentation does not explicitly state any margin outlook or guidance for future quarters in terms of EBITDA or operating margin.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
The presentation does not explicitly mention any specific capital expenditure (capex), capacity expansion plans, new plants, or projects with amounts, status, or timelines.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.